TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06209905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge augmentation
Description: Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Alveolar ridge augmentation
Description: Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
Study: NCT04868318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very-high protein enteral formula
Description: Peptamen® Intense VHP (37% protein)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-high protein enteral formula
Description: Peptamen® (16% protein)
Study: NCT05067543

Intervention type: DEVICE
Intervention: Tornier Perform Humeral - Stem
Description: The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
Study: NCT06196073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manual therapy
Description: Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
Study: NCT04807283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure
Description: Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
Study: NCT06401785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen capsules
Description: In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen capsules
Description: In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
Study: NCT05205252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat
Description: Orally, twice daily in continuous 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat
Description: Orally, twice daily in continuous 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat
Description: Orally, twice daily in continuous 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat
Description: Orally, twice daily in continuous 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat
Description: Orally, twice daily in continuous 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafasitamab
Description: Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Orally, 100 mg, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab (Intravenously)
Description: Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosunetuzumab
Description: Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab (Subcutaneously)
Description: Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase-Fihj
Description: Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 20mg
Description: Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
Study: NCT05599646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional pedometer based walking intervention
Description: Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gamified pedometer based walking intervention
Description: Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
Study: NCT05427019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal adductor canal block
Description: All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal adductor canal block and Periarticular block
Description: All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
Study: NCT05861778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Girentuximab
Description: A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
Study: NCT06295887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation
Description: Simulation program using VR or simulator that mimics patient's desaturation
Study: NCT05193747

Intervention type: OTHER
Intervention: Anesthesia depth monitoring
Description: BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
Study: NCT06295887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation
Description: Simulation program using VR or simulator that mimics patient's desaturation
Study: NCT05532176

Intervention type: OTHER
Group type: OTHER
Intervention: Posture standards
Description: Dynamic and static Postural measurements according to four types of tests
Study: NCT06258187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedi-Cap
Description: The neonatal resuscitation team will include or omit the use of Pedi-Cap during non-invasive positive pressure ventilation (PPV) for infants ≥30 weeks in the delivery room based on the randomized study arm each month.
Study: NCT06320041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oxelidine group
Description: Analgesic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose oxelidine group
Description: Analgesic dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone group
Description: Analgesic dose
Study: NCT06090097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeBRIGHT System
Description: The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercise
Description: The control group will complete a 10-week regimen of conventional PT exercise
Study: NCT05294991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness app intervention #1
Description: This is the active intervention group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness app intervention #2
Description: This is the active comparator/control group.
Study: NCT05209841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose heparin
Description: Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Catheters will be sealed with 3mL of 0.9% sodium chloride
Study: NCT05432050

Intervention type: DEVICE
Intervention: Bispectral index and Patient state index monitoring
Description: The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
Study: NCT04936698

Intervention type: DRUG
Intervention: PTU 50 MG Oral Tablet
Description: to treat if the patient has hyperthyroidism

Intervention type: DRUG
Intervention: Levothyroxin
Description: to treat if the patient has hypothyroidism
Study: NCT05654805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drinking powder supplement
Description: Drinking powder supplement, to be taken twice daily over 12 weeks
Study: NCT06250634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole + amoxicillin
Description: esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent
Description: 20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan + amoxicillin
Description: 20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan + amoxicillin + clarithromycin
Description: 20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
Study: NCT05654805

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Drinking powder supplement
Description: Drinking powder supplement, to be taken twice daily over 12 weeks
Study: NCT05721209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Mill with AR/VR Guidance
Description: Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
Study: NCT06499012

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: All-plant Protein Booster Product Group
Description: Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
Study: NCT04787328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
Study: NCT05582369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Rewards Messages
Description: Messages about the affective rewards of exercise
Study: NCT05409079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abilitech Assist
Description: The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
Study: NCT04857918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual running group program
Description: The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
Study: NCT04857918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control: Fitness Application Strava
Description: The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
Study: NCT04156945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Description: An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Description: An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV RNA home-based test
Description: An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
Study: NCT05721209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mill without AR/VR Guidance
Description: Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mill without AR/VR Guidance
Description: Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeno 3-Layer Walkway
Description: Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeno 3-Layer Walkway
Description: Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zeno 3-Layer Walkway
Description: Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zeno 3-Layer Walkway
Description: Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hunova
Description: Used to conduct fall-risk assessment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hunova
Description: Used to conduct fall-risk assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hunova
Description: Used to conduct fall-risk assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hunova
Description: Used to conduct fall-risk assessment.
Study: NCT06355128

Intervention type: OTHER
Intervention: NOT
Description: NOT

Intervention type: OTHER
Intervention: NOT
Description: NOT

Intervention type: OTHER
Intervention: NOT
Description: NOT
Study: NCT05727488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
Study: NCT05300997

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
Study: NCT05934656

Intervention type: OTHER
Intervention: Latent class analysis
Description: The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation.
Study: NCT04156945

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV RNA home-based test
Description: An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.